Clinical experience in idiopathic pulmonary fibrosis: a retrospective study

References

• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.10.1164/rccm.2009-040GL
   PubMed Web of Science ®Google Scholar
• Guiot J, Corhay JL, Louis R. Idiopathic pulmonary fibrosis. Rev Med Liege. 2014;69(11):605–610.
   PubMedGoogle Scholar
• Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–816.10.1164/rccm.200602-163OC
   PubMed Web of Science ®Google Scholar
• Kaunisto J, Salomaa E-R, Hodgson U, et al. Idiopathic pulmonary fibrosis – a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med. 2013;13(1):53.10.1186/1471-2466-13-53
   PubMed Web of Science ®Google Scholar
• Travis WD, Costabel U, Hansell DM, et al. An Official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748.10.1164/rccm.201308-1483ST
   PubMed Web of Science ®Google Scholar
• Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J. 2011;37(4):743–746.10.1183/09031936.00017711
   PubMed Web of Science ®Google Scholar
• Raghu G, Chen S-Y, Hou Q, et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur Respir J. 2016;48(1):179–186.10.1183/13993003.01653-2015
   PubMed Web of Science ®Google Scholar
• Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS ONE. 2010;5(1):e8959.10.1371/journal.pone.0008959
   PubMed Web of Science ®Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.10.1056/NEJMoa1402582
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.10.1056/NEJMoa1402584
   PubMed Web of Science ®Google Scholar
• Maher TM. profileing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev. 2013;22(128):148–152.10.1183/09059180.00000913
   PubMedGoogle Scholar
• Guiot J, Bondue B, Henket M, et al. Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. BMC Pulm Med. 2016;16(1):86.10.1186/s12890-016-0249-6
   PubMed Web of Science ®Google Scholar
• Guiot J, Henket M, Corhay JL, et al. Sputum biomarkers in IPF: evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7. In: Morty RE, editor. PLoS ONE. Vol. 12. San Francisco (CA): Public Library of Science; 2017. p. e0171344.
   Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2015;47(1):ERJ-00026.
   Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19.10.1164/rccm.201506-1063ST
   PubMed Web of Science ®Google Scholar
• Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–691.10.7326/0003-4819-156-10-201205150-00004
   Google Scholar
• Kishaba T, Nagano H, Nei Y, et al. Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis. 2016;8(6):1112–1120.
   PubMed Web of Science ®Google Scholar
• Guiot J, Moermans C, Henket M, et al. Blood biomarkers in idiopathic pulmonary fibrosis. Lung. 2017;195(3):273–280.10.1007/s00408-017-9993-5
   PubMed Web of Science ®Google Scholar